PDEδ critically regulates oncogenic KRAS membrane localization and signal transduction, with KRAS mutations driving ~30% of lung, 45% of colorectal, and 90% of pancreatic cancers. This evidence concerns the gene KRAS and familial pancreatic carcinoma.